Oren J. Becher

Northwestern University — United States

Medicine · Health Sciences

42h-index8.4kcitations325works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(189), Epigenetics and DNA Methylation(42), Neuroblastoma Research and Treatments(31), Chromatin Remodeling and Cancer(25), MicroRNA in disease regulation(24)

Publications317 total

EXTH-69. CD155 regulates tumor growth and immune evasion in diffuse midline glioma
Neuro-Oncology·2025Open Access
CD155 regulates tumor growth and immune evasion in diffuse midline glioma
2025Open Access
A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon
npj Precision Oncology·2025Open Access
Challenging the Odds: Long‐Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co‐Mutations Treated With Upfront Radiotherapy and Targeted Therapy
Pediatric Blood & Cancer·2025Open Access
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas
Cell Reports Medicine·2025· 3 citedOpen Access
Disruption of ataxia telangiectasia–mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models
Journal of Clinical Investigation·2025· 2 citedOpen Access
Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models
2025Open Access
IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas
Acta Neuropathologica Communications·2025· 2 citedOpen Access
A clinically relevant model and method to study necrosis as a driving force in glioma restructuring and progression
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma
Neuro-Oncology Advances·2025Open Access
IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas
2024Open Access
TMIC-36. EVALUATING PHARMACOLOGICAL INHIBITION OF LSD1 IN MODELS OF DIFFUSE MIDLINE GLIOMA AND EFFECTS ON IMMUNE MICROENVIRONMENT SIGNALING
Neuro-Oncology·2024Open Access
TMIC-06. TUMOR ASSOCIATED MACROPHAGES DRIVE TUMOR PROGRESSION AND ARE TRANSCRIPTIONALLY SHAPED BY HISTONE MUTATIONS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2024Open Access
Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations
Immunity·2024· 20 citedOpen Access
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models
JCI Insight·2024· 4 citedOpen Access
Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma
Acta Neuropathologica·2024· 21 citedOpen Access
DIPG-75. PHARMACOLOGICAL INHIBITION OF LSD1/KDM1A IN DIFFUSE MIDLINE GLIOMA MODELS AND IMPACT ON KINASE SIGNALING
Neuro-Oncology·2024Open Access
DIPG-89. ENHANCEMENT OF BLOOD-BRAIN BARRIER PENETRATION AND TUMOR TARGETED DRUG DELIVERY FOR DMG USING A P-SELECTIN TARGETED NANOMEDICINE APPROACH
Neuro-Oncology·2024Open Access
DIPG-83. RBPJ-SIX1 AS A TUMOR SUPPRESSOR AXIS IN DIFFUSE INTRINSIC PONTINE GLIOMA
Neuro-Oncology·2024Open Access
BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma
Journal of Clinical Investigation·2024· 13 citedOpen Access
page 1 of 16Next →

Frequent Co-authors

Dolores Hambardzumyan(11), Francisco J. Cordero(8), Javad Nazarian(7), Eric C. Holland(7), Cynthia Hawkins(6), Katherine L. Misuraca(6), Rintaro Hashizume(6), Ira J. Dunkel(6), Christine M. Hoeman(5), Chris Jones(5), Guo Hu(5), Kelly L. Barton(5), Tobey J. MacDonald(5), Stephen W. Gilheeney(4), Yasmin Khakoo(4), Pawel Buczkowicz(3), Éric Bouffet(3), Ute Bartels(3), Alan Mackay(3), Mark M. Souweidane(3)